Amryt Pharma PLC Senior Management Appointment
March 06 2018 - 2:01AM
RNS Non-Regulatory
TIDMAMYT
Amryt Pharma PLC
06 March 2018
6 March 2018
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Senior Management Appointment
Amryt, a biopharmaceutical company focused on treatments for
rare and orphan diseases, is pleased to announce the appointment of
Jordi Casals as the Company's Head of Europe.
Jordi will be responsible for leading and further developing
Amryt's European operations, including product launches. His
initial focus is on the continuing sales growth of the Company's
commercial asset, Lojuxta, a treatment for adult patients with
Homozygous Familial Hypercholesterolaemia.
Jordi has over 20 years' experience in the pharmaceutical and
biotech industry. Most recently, he worked for Aegerion
Pharmaceuticals as a Consultant, managing its commercial operations
in the Iberia region. Before that, he worked for eight years at
Alexion Pharmaceuticals, latterly as VP Commercial Operations
Western Europe. He has also held sales and marketing roles at
Grifols S.A., the European multinational pharmaceutical, and Otsuka
Pharmaceutical Europe, the Japan-based pharmaceutical company.
Jordi holds an MBA from UPC University, Barcelona, together with
a Pharmacy Degree from Barcelona University.
Dr. Joe Wiley, Chief Executive Officer, commented:
"I am pleased to welcome Jordi to our senior management team as
the Company's Head of Europe. His significant commercial experience
of European markets will help us to drive and further develop
Amryt's growth across this key region."
Enquiries:
Amryt Pharma plc +353 (1) 518 0200
Joe Wiley, CEO
Rory Nealon, CFO/COO
KTZ Communications +44 (0) 20 3178 6378
Katie Tzouliadis, Irene
Bermont-Penn, Emma Pearson
About Amryt Pharma plc
(www.amrytpharma.com)
Amryt Pharma is a specialty biopharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or orphan diseases. The Company is
building a diversified portfolio of commercially attractive,
best-in-class, proprietary new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
The Company holds an exclusive licence to sell Lojuxta
(lomitapide) for adults, across the European Economic Area, Middle
East and North Africa, Turkey and Israel. Lojuxta is used to treat
a rare life-threatening disease called Homozygous Familial
Hypercholesterolaemia, which impairs the body's ability to remove
LDL cholesterol ("bad" cholesterol) from the blood. This typically
results in extremely high blood LDL cholesterol levels, leading to
aggressive and premature narrowing and blocking of arterial blood
vessels. If left untreated, heart attack or sudden death may occur
in childhood or early adulthood.
Amryt's lead drug candidate, AP101, is a potential treatment for
Epidermolysis bullosa ("EB"), a rare and distressing genetic skin
disorder affecting young children for which there is currently no
treatment. It is currently in Phase III clinical trials. The global
market opportunity for EB is estimated to be in excess of EUR 1.3
billion.
Amryt's earlier stage product AP102 is focused on developing
novel, next generation somatostatin analogue ("SSA") peptide
medicines for patients with rare neuroendocrine diseases, where
there is a high unmet medical need, including acromegaly and
Cushing's disease.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAQELFBVXFEBBF
(END) Dow Jones Newswires
March 06, 2018 02:01 ET (07:01 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024